Pharma-Bio Serv (PBSV) Net Income towards Common Stockholders (2010 - 2026)
Pharma-Bio Serv's (PBSV) quarterly Net Income towards Common Stockholders came in at $232986.0 in Q2 2026, up 144.34% on a YoY basis from $95353.0 in Q2 2025, and up 609.03% quarter-over-quarter from $32860.0 in Q1 2026.
Powered by 
Analysis
Pharma-Bio Serv (PBSV) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Pharma-Bio Serv (PBSV) has reported Net Income towards Common Stockholders for 17 consecutive years, with $232986.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 144.34% year-over-year to $232986.0; the trailing twelve-month figure through Apr 2026 stood at $51936.0 (up 127.45% YoY), and the FY2025 full-year result was -$100463.0, up 87.08% from the prior year.
- Net Income towards Common Stockholders grew to $232986.0 in Q2 2026 per PBSV's latest filing, from $32860.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $526242.0 in Q3 2023 and bottomed at -$309194.0 in Q3 2024.
- Historically, Net Income towards Common Stockholders has averaged $94170.6 across 5 years, with a median of $64106.5 in 2025.
- The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders plunged 163.48% in 2024, then surged 284.96% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at $173379.0 in 2022, then plunged by 127.19% to -$47148.0 in 2023, then soared by 134.17% to $16111.0 in 2024, then sank by 100.63% to -$102.0 in 2025, then jumped by 228517.65% to $232986.0 in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $232986.0, $32860.0, and -$102.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 124.62 Bn | 115.58 Bn | 6.13 Bn | 2.39 Bn |
| 2 | UL Solutions | 14.92 Bn | 14.51 Bn | 417.00 Mn | 254.00 Mn |
| 3 | Gartner | 11.76 Bn | 10.28 Bn | 1.19 Bn | 275.50 Mn |
| 4 | Tetra Tech | 9.19 Bn | 8.96 Bn | 243.21 Mn | 109.58 Mn |
| 5 | Booz Allen Hamilton Holding | 8.76 Bn | 8.22 Bn | 1.46 Bn | 198.00 Mn |
| 6 | Genpact | 6.27 Bn | 5.75 Bn | 490.34 Mn | 145.74 Mn |
| 7 | Korn Ferry | 4.28 Bn | 3.15 Bn | 685.99 Mn | 73.85 Mn |
| 8 | Fti Consulting | 4.20 Bn | 4.04 Bn | 316.27 Mn | 57.81 Mn |
| 9 | Grand Canyon Education | 4.01 Bn | 3.73 Bn | 204.08 Mn | 45.85 Mn |
| 10 | Pharma-Bio Serv | 12.37 Mn | 3.89 Mn | 902,041.00 | 232,986.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 232,986.00 |
| Jan 31, 2026 | 32,860.00 |
| Oct 31, 2025 | -102.00 |
| Jul 31, 2025 | -213,808.00 |
| Apr 30, 2025 | 95,353.00 |
| Jan 31, 2025 | 8,536.00 |
| Oct 31, 2024 | 16,111.00 |
| Jul 31, 2024 | -309,194.00 |
| Apr 30, 2024 | -213,817.00 |
| Jan 31, 2024 | -270,719.00 |
| Oct 31, 2023 | -47,148.00 |
| Jul 31, 2023 | 526,242.00 |
| Apr 30, 2023 | 404,654.00 |
| Jan 31, 2023 | 426,432.00 |
| Oct 31, 2022 | 173,379.00 |
| Jul 31, 2022 | 288,034.00 |
| Apr 30, 2022 | 240,027.00 |
| Jan 31, 2022 | 305,244.00 |
| Oct 31, 2021 | -4.87 Mn |
| Jul 31, 2021 | 2.28 Mn |